Marc Casper, Thermo Fisher CEO (Suzanne Kreiter/The Boston Globe via Getty Images)

Ther­mo Fish­er wa­gers on ear­ly can­cer di­ag­nos­tics in $2.6B cash deal for mul­ti­ple myelo­ma test mak­er

Al­ways on the look­out for the next thing to buy, Ther­mo Fish­er Sci­en­tif­ic has set­tled on an on­col­o­gy di­ag­nos­tic play­er for its lat­est ac­qui­si­tion.

The life sci­ences con­glom­er­ate is shelling out $2.6 bil­lion (£2.25 bil­lion) to ac­quire The Bind­ing Site Group from a group of pri­vate eq­ui­ty in­vestors, in­te­grat­ing a suite of di­ag­nos­tic as­says and in­stru­ments for blood can­cers and im­mune sys­tem dis­or­ders in­to its spe­cial­ty di­ag­nos­tics busi­ness.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.